Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Buserelin acetate
Drug ID BADD_D00315
Description Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). It is used in prostate cancer treatment.
Indications and Usage Buserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.
Marketing Status approved; investigational
ATC Code L02AE01
DrugBank ID DB06719
KEGG ID D01831
MeSH ID D002064
PubChem ID 50224
TTD Drug ID D04GSY
NDC Product Code 71052-358
UNII 13U86G7YSP
Synonyms Buserelin | Buserelin Acetate | Acetate, Buserelin | Suprefact | Profact | Receptal | Tiloryth | Suprecur | Bigonist | HOE-766 | HOE 766 | HOE766
Chemical Information
Molecular Formula C62H90N16O15
CAS Registry Number 68630-75-1
SMILES CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=C C=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC( =O)N6.CC(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain lower07.01.05.010--Not Available
Abdominal pain upper07.01.05.003--
Abortion spontaneous18.01.04.001--Not Available
Accommodation disorder06.02.04.001--Not Available
Acne23.02.01.001--Not Available
Administration site reaction12.07.04.011; 08.02.04.011--Not Available
Amnesia19.20.01.001; 17.03.02.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Anxiety19.06.02.002--
Application site pain12.07.01.004; 08.02.01.004--Not Available
Application site reaction12.07.01.006; 08.02.01.006--Not Available
Arthralgia15.01.02.001--
Asthenia08.01.01.001--Not Available
Asthma10.01.03.010; 22.03.01.002--Not Available
Atrophy08.03.04.001--Not Available
Auditory disorder04.02.03.002--Not Available
Back pain15.03.04.005--
Blood oestrogen decreased13.10.05.010--Not Available
Blood testosterone increased13.10.05.002--Not Available
Body temperature increased13.15.01.001--Not Available
Bone pain15.02.01.001--
Breast atrophy21.05.04.005--
Breast enlargement21.05.04.001--Not Available
Breast pain21.05.05.003--
Breast tenderness21.05.05.004--Not Available
Condition aggravated08.01.03.004--Not Available
Constipation07.02.02.001--
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages